NIBEC Co., Ltd.'s (KOSDAQ:138610) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Sep 26
Have your own idea? Try our Stock Screener
South Korean (KOSPI) Biotech Industry Analysis
UpdatedSep 26, 2025
DataAggregated Company Financials
Companies121
- 7D0.6%
- 3M13.3%
- 1Y19.4%
- YTD27.8%
Last week, the Biotech industry hasn't moved much but Celltrion is up 4.4% in that time. The past year has been better, since the industry has gained 19% in that time. As for the next few years, earnings are expected to grow by 40% per annum.
Industry Valuation and Performance
Has the South Korean Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 27 Sep 2025 | ₩121.4t | ₩12.4t | -₩85,312,629,648.00 | 28x | -1423.2x | 9.8x |
| Mon, 25 Aug 2025 | ₩111.0t | ₩12.3t | -₩27,717,663,163.00 | 21.7x | -4004.5x | 9x |
| Wed, 23 Jul 2025 | ₩116.6t | ₩11.8t | -₩227,694,607,523.00 | 24.8x | -511.9x | 9.9x |
| Fri, 20 Jun 2025 | ₩105.1t | ₩11.8t | -₩110,463,137,023.00 | 26.2x | -951.2x | 8.9x |
| Sun, 18 May 2025 | ₩93.5t | ₩11.4t | -₩460,034,107,555.00 | 28.1x | -203.2x | 8.2x |
| Tue, 15 Apr 2025 | ₩98.9t | ₩11.4t | -₩488,600,830,556.00 | 26.7x | -202.3x | 8.7x |
| Thu, 13 Mar 2025 | ₩100.4t | ₩10.6t | -₩926,234,823,851.00 | 28.2x | -108.4x | 9.4x |
| Sat, 08 Feb 2025 | ₩96.4t | ₩10.5t | -₩1,010,177,767,831.00 | 24.5x | -95.4x | 9.2x |
| Mon, 06 Jan 2025 | ₩93.7t | ₩10.5t | -₩1,004,347,149,181.00 | 25.1x | -93.3x | 9x |
| Wed, 04 Dec 2024 | ₩91.1t | ₩10.5t | -₩999,537,042,058.00 | 24.3x | -91.2x | 8.7x |
| Fri, 01 Nov 2024 | ₩97.0t | ₩10.3t | -₩653,791,712,887.00 | 27.5x | -148.4x | 9.4x |
| Sun, 29 Sep 2024 | ₩93.5t | ₩10.3t | -₩663,859,541,267.00 | 24.3x | -140.9x | 9.1x |
| Tue, 27 Aug 2024 | ₩96.2t | ₩10.2t | -₩678,076,049,438.00 | 23.4x | -141.8x | 9.4x |
| Thu, 25 Jul 2024 | ₩91.4t | ₩9.9t | -₩651,620,427,048.00 | 23.8x | -140.2x | 9.3x |
| Sat, 22 Jun 2024 | ₩83.5t | ₩9.9t | -₩635,976,480,448.00 | 21.9x | -131.3x | 8.5x |
| Mon, 20 May 2024 | ₩82.6t | ₩9.6t | -₩558,637,135,118.00 | 23.4x | -147.9x | 8.6x |
| Wed, 17 Apr 2024 | ₩78.9t | ₩9.6t | -₩589,100,786,928.00 | 21.9x | -133.9x | 8.2x |
| Fri, 15 Mar 2024 | ₩81.8t | ₩9.7t | -₩529,895,238,747.00 | 56.7x | -154.4x | 8.4x |
| Sun, 11 Feb 2024 | ₩73.3t | ₩9.7t | -₩537,261,689,777.00 | 62.6x | -136.4x | 7.5x |
| Tue, 09 Jan 2024 | ₩67.0t | ₩10.1t | -₩324,278,048,367.00 | 30x | -206.6x | 6.6x |
| Thu, 07 Dec 2023 | ₩57.6t | ₩10.1t | -₩309,980,431,097.00 | 28x | -185.9x | 5.7x |
| Sat, 04 Nov 2023 | ₩54.2t | ₩10.2t | -₩239,053,318,689.00 | 30.2x | -226.6x | 5.3x |
| Mon, 02 Oct 2023 | ₩55.5t | ₩10.2t | -₩239,053,318,689.00 | 28.3x | -232.1x | 5.4x |
| Wed, 30 Aug 2023 | ₩58.0t | ₩10.1t | -₩379,278,146,849.00 | 35.5x | -152.9x | 5.7x |
| Fri, 28 Jul 2023 | ₩54.6t | ₩10.3t | -₩151,534,704,579.00 | 25.8x | -360.4x | 5.3x |
| Sun, 25 Jun 2023 | ₩59.4t | ₩10.3t | -₩151,534,704,579.00 | 29.8x | -391.7x | 5.8x |
| Tue, 23 May 2023 | ₩63.7t | ₩11.0t | ₩317.7b | 31.4x | 200.5x | 5.8x |
| Thu, 20 Apr 2023 | ₩64.0t | ₩11.0t | ₩317.9b | 24.7x | 201.3x | 5.8x |
| Sat, 18 Mar 2023 | ₩57.4t | ₩11.3t | ₩956.2b | 23.6x | 60.1x | 5.1x |
| Mon, 13 Feb 2023 | ₩59.7t | ₩11.3t | ₩970.8b | 24.6x | 61.5x | 5.3x |
| Wed, 11 Jan 2023 | ₩59.2t | ₩11.4t | ₩685.0b | 22.7x | 86.5x | 5.2x |
| Fri, 09 Dec 2022 | ₩60.2t | ₩10.8t | ₩197.4b | 23x | 305x | 5.6x |
| Sun, 06 Nov 2022 | ₩60.5t | ₩10.8t | ₩348.0b | 18.7x | 173.8x | 5.6x |
| Tue, 04 Oct 2022 | ₩57.1t | ₩10.8t | ₩392.8b | 20.1x | 145.3x | 5.3x |
Price to Earnings Ratio
145.3x
Current Industry PE
- Investors are optimistic on the South Korean Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 7.4x is lower than the industry's current PS ratio of 9.8x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 4.8% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare industry?
| KR Market | 0.32% | |
| Healthcare | 0.17% | |
| Biotech | 0.57% | |
| Biotech | 0.57% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A068270 Celltrion | ₩178.00k | 4.2% +₩1.6t | -0.2% | PE79.7x | |
| A347850 D&D Pharmatech | ₩199.60k | 20.3% +₩371.8b | 394.1% | PS232.2x | |
| A950160 Kolon TissueGene | ₩47.30k | 4.9% +₩182.9b | 243.3% | PS714.9x | |
| A115180 Qurient | ₩15.84k | 17.4% +₩89.3b | 261.6% | PS68x | |
| A468530 Proteina | ₩41.40k | 24.3% +₩88.1b | n/a | n/a |
